Head-To-Head Contrast: IN8bio (NASDAQ:INAB) and Windtree Therapeutics (NASDAQ:WINT)

IN8bio (NASDAQ:INAB) and Windtree Therapeutics (NASDAQ:WINT) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, earnings, dividends, analyst recommendations, institutional ownership and profitability.

Profitability

This table compares IN8bio and Windtree Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
IN8bio	N/A	-197.15%	-130.48%
Windtree Therapeutics	N/A	-362.76%	-79.65%

Earnings & Valuation

This table compares IN8bio and Windtree Therapeutics”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IN8bio	N/A	N/A	-$30.01 million	($0.75)	-0.33
Windtree Therapeutics	N/A	N/A	-$20.29 million	($16.47)	-0.01

IN8bio is trading at a lower price-to-earnings ratio than Windtree Therapeutics, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a summary of current ratings and recommmendations for IN8bio and Windtree Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IN8bio	0	0	2	0	3.00
Windtree Therapeutics	0	1	0	0	2.00

IN8bio currently has a consensus price target of $7.75, indicating a potential upside of 3,026.26%. Windtree Therapeutics has a consensus price target of $7.00, indicating a potential upside of 5,123.88%. Given Windtree Therapeutics’ higher possible upside, analysts plainly believe Windtree Therapeutics is more favorable than IN8bio.

Institutional & Insider Ownership

92.1% of IN8bio shares are held by institutional investors. Comparatively, 29.3% of Windtree Therapeutics shares are held by institutional investors. 15.5% of IN8bio shares are held by insiders. Comparatively, 0.3% of Windtree Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Risk & Volatility

IN8bio has a beta of 0.04, meaning that its stock price is 96% less volatile than the S&P 500. Comparatively, Windtree Therapeutics has a beta of 0.57, meaning that its stock price is 43% less volatile than the S&P 500.

Summary

IN8bio beats Windtree Therapeutics on 6 of the 11 factors compared between the two stocks.

About IN8bio

IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM. It also develops INB-300, INB-410, and INB-500 that are in preclinical Phase for treatment of various solid tumor cancers. The company was formerly known as Incysus Therapeutics, Inc. and changed its name to IN8bio, Inc. in August 2020. IN8bio, Inc. was incorporated in 2016 and is headquartered in New York, New York.

About Windtree Therapeutics

Windtree Therapeutics, Inc., a biotechnology company, focuses on the development of therapeutics for the treatment of acute cardiovascular diseases. The company’s lead product candidate is istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as for the treatment of early cardiogenic shock. It also develops AEROSURF, an aerosolized KL4 surfactant that is in Phase 2b clinical trial to treat respiratory distress syndrome in premature infants; Surfaxin, a lyophilized KL4 surfactant, which is in Phase 2a clinical trial for the treatment of lung injury resulting from COVID-19; Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension; and oral and intravenous SERCA2a activator, which is in preclinical trial for the treatment of chronic and acute heart failure. In addition, it is developing aPKCi Inhibitor for the treatment of cutaneous malignancies and solid tumors that is in preclinical trials. Windtree Therapeutics, Inc. has a collaboration with Universita degli Studi di Milano-Bicocca for the discovery and development of new SERCA2a compounds for the treatment of chronic and acute human heart failure; a strategic alliance with Laboratorios del Dr. Esteve, S.A. for the development, marketing, and sale of a portfolio of potential KL4 surfactant products; license, development and commercialization agreement with Lee’s Pharmaceutical (HK) Ltd. and Zhaoke Pharmaceutical (Hefei) Co. Ltd.; license agreement with Philip Morris USA, Inc. and Johnson & Johnson; and collaboration with Battelle Memorial Institute for development of its ADS for use in its phase III program. The company was formerly known as Discovery Laboratories, Inc. and changed its name to Windtree Therapeutics, Inc. in April 2016. The company was founded in 1992 and is headquartered in Warrington, Pennsylvania.